Clinical Trials Logo

Clinical Trial Summary

This randomized pilot clinical trial studies sildenafil citrate before surgery in improving kidney function in patients with kidney cancer. Sildenafil citrate may help protect the kidney from the side effects of surgery and improve kidney function after surgery.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To assess accrual, retention, and participation rates for patients receiving sildenafil (sildenafil citrate) compared to placebo in patients undergoing robotic partial nephrectomy (RPN) for a suspected renal malignancy.

SECONDARY OBJECTIVES:

I. To evaluate individual alterations in glomerular filtration rate (GFR) at 24 hours, 48 hours and one month following RPN and compare these to the placebo group.

II. To evaluate individual alterations in proteinuria at 24 hours, 48 hours, one month and three months following RPN and compare these to the placebo group.

III. To measure between-group differences in estimated blood loss and hemoglobin concentration at 24 hours following RPN.

IV. To describe individual changes in blood pressure measurements as noted in the preoperative holding area, throughout the procedure and in the post-anesthesia care unit.

V. To describe between-group variations in vasopressor support or intravenous fluid requirements during the operative procedure.

VI. To compare overall complication rates (within 90 days postoperatively) between groups.

VII. To obtain a preliminary effect size of sildenafil on change in GFR at three months following RPN.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sildenafil citrate orally (PO) before the initiation of standard robotic partial nephrectomy.

ARM II: Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.

After completion of study treatment, patients are followed up at 1 and 3 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01950923
Study type Interventional
Source Wake Forest University Health Sciences
Contact
Status Completed
Phase Phase 1
Start date September 2013
Completion date March 2016

See also
  Status Clinical Trial Phase
Withdrawn NCT01688414 - Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer N/A
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Active, not recruiting NCT03819569 - GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses N/A
Recruiting NCT06056505 - Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy N/A
Recruiting NCT01967407 - IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. Phase 1/Phase 2
Terminated NCT00960063 - A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) Phase 1
Recruiting NCT05890781 - Engineering Immune Organoids to Study Pediatric Cancer N/A
Completed NCT05015179 - Mixed Reality Technology in Laparoscopic Partial Nephrectomy N/A
Completed NCT00019630 - Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors Phase 1
Completed NCT01908166 - Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions N/A
Recruiting NCT05728957 - Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors